Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cabamiquine - Merck Serono

Next Previous
Search
Drug Profile

Cabamiquine - Merck Serono

Alternative Names: DDD-107498; DDD498; GTPL9737; M-5717; MM5717; MMV-121

Latest Information Update: 10 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medicines for Malaria Venture; University of Dundee
  • Developer Merck Serono
  • Class Amides; Antimalarials; Fluorinated hydrocarbons; Morpholines; Pyrrolidines; Quinolines; Small molecules
  • Mechanism of Action Peptide elongation factor 2 inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Falciparum malaria
  • No development reported Malaria

Most Recent Events

  • 12 Dec 2024 Merck KGaA completes a phase IIa CAPTURE 2 trial in Falciparum malaria (Combination therapy, In adolescents, In adults) in Burkina Faso, Gambia, Kenya, Zambia (PO, Capsule) (NCT05974267)
  • 28 May 2024 Merck KGaA completes a phase IIa CAPTURE 1 trial for Falciparum malaria (Combination therapy, In Adolescents, In children, In adults) (PO, Granules) in Burkina Faso, Gabon, Mozambique, Uganda (NCT05689047)
  • 28 Nov 2023 Phase-II clinical trials in Falciparum malaria (Combination therapy, In adolescents, In adults) in Kenya, Burkina Faso, Gambia, Zambia (PO) (NCT05974267)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top